Clinical Features, Metabolic Associated Fatty Liver Disease
Conditions
Keywords
Metabolic associated fatty liver disease, Clinical features
Brief summary
Metabolic associated fatty liver disease (MAFLD), which can lead to liver fibrosis, cirrhosis, liver failure and even hepatocellular carcinoma, poses a significant burden on society. With the improvement of living standards and changes in dietary habits, MAFLD patients show a younger and increasing trend, but there is still no specific drug. The clinical features and prognosis of MAFLD may be different with different metabolic disorder phenotypes and treatment measures. Therefore, further systematic study of the clinical characteristics and prognosis of MAFLD patients will be of great significance for the formulation of corresponding clinical prevention and treatment strategies.
Detailed description
Metabolic associated fatty liver disease (MAFLD), which can lead to liver fibrosis, cirrhosis, liver failure and even hepatocellular carcinoma, poses a significant burden on society. With the improvement of living standards and changes in dietary habits, MAFLD patients show a younger and increasing trend, but there is still no specific drug. The clinical features and prognosis of MAFLD may be different with different metabolic disorder phenotypes and treatment measures. Therefore, further systematic study of the clinical characteristics and prognosis of MAFLD patients will be of great significance for the formulation of corresponding clinical prevention and treatment strategies.
Interventions
None listed
Sponsors
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. 18 years or older; 2. MAFLD patients
Exclusion criteria
1. malignant tumors; 2. mental illness, severe impairment of cardiopulmonary function, severe renal insufficiency, severe infections, and cerebrovascular accidents; 3. received liver or other organ transplants.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinical characteristics and follow-up outcomes of MAFLD patients | 480 weeks | 1. Clinical characteristic related indicators: height (m), weight (kg), waist circumference (cm), previous history (T2DM, HT, dyslipidemia), SBP (mmHg), DBP (mmHg), alcohol intake (g/week), smoking, blood routine \[WBC (109/L), Hb (g/L), PLT (109/L)\], CRP (mg/L), biochemical indicators \[TB (umol/L), ALB (g/L), ALT (U/L), AST (U/L), ALP (U/L), GGT (U/L), TC (mmol/L), TG (mmol/L), HDL (mmol/L), LDL (mmol/L)\], blood glucose indicators \[FBG (mmol/L), PBG (mmol/L), HA1c (%)\], coagulation \[PT (s), INR\], AFP (ng/ml), transient elastography \[LSM (Kpa), ACP (dB/m)\], liver CT/MRI/B type ultrasound. 2. Follow up outcome data: mortality and causes of death, incidence of complications (ascites, variceal bleeding, hepatic encephalopathy, hepatorenal syndrome, intrahepatic and extrahepatic malignancies, infection, cardiovascular and cerebrovascular diseases, or all-cause mortality). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clinical characteristics and follow-up outcomes of MAFLD patients under different subgroups | 480 weeks | 1. Subgroups: Age (\<40 years and ≥40 years), gender (male and female), steatosis stage according to CT/MRI/B type ultrasound (Mild, moderate, and severe), and MASH status (non-MASH and MASH) 2. Clinical characteristic related indicators: height (m), weight (kg), waist circumference (cm), previous history (T2DM, HT, dyslipidemia), SBP (mmHg), DBP (mmHg), alcohol intake (g/week), smoking, WBC (109/L), Hb (g/L), PLT (109/L), TB (umol/L), ALB (g/L), ALT (U/L), AST (U/L), ALP (U/L), GGT (U/L), TC (mmol/L), TG (mmol/L), HDL (mmol/L), LDL (mmol/L), FBG (mmol/L), PBG (mmol/L), HA1c (%), PT (s), INR, AFP (ng/ml), transient elastography \[LSM (Kpa), ACP (dB/m)\], liver CT/MRI/B type ultrasound, liver histology. 3. Follow up outcome data: mortality and causes of death, incidence of complications. |
| Baseline clinical characteristics MAFLD patients | 0 weeks | Clinical characteristic related indicators: height (m), weight (kg), waist circumference (cm), previous history (T2DM, HT, dyslipidemia), SBP (mmHg), DBP (mmHg), alcohol intake (g/week), smoking, blood routine \[WBC (109/L), Hb (g/L), PLT (109/L)\], CRP (mg/L), biochemical indicators \[TB (umol/L), ALB (g/L), ALT (U/L), AST (U/L), ALP (U/L), GGT (U/L), TC (mmol/L), TG (mmol/L), HDL (mmol/L), LDL (mmol/L)\], blood glucose indicators \[FBG (mmol/L), PBG (mmol/L), HA1c (%)\], coagulation \[PT (s), INR\], AFP (ng/ml), transient elastography \[LSM (Kpa), ACP (dB/m)\], liver CT/MRI/B type ultrasound. |
| Risk factors for progression to cirrhosis and hepatocellular carcinoma | 480 weeks | Risk factors for progression to cirrhosis and hepatocellular carcinoma in MAFLD patients |
Countries
China
Contacts
Primary ContactJie Li, M.D.,Ph.D
Backup ContactQianqian Chen
Outcome results
None listed